{"id":"W3186485642","doi":"10.1182/bloodadvances.2021004770","title":"Prognostic significance of <i>FCGR2B</i> expression for the response of DLBCL patients to rituximab or obinutuzumab treatment","year":2021,"lang":"en","type":"article","venue":"Blood Advances","topic":"Monoclonal and Polyclonal Antibodies Research","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"ca_institutions":"Simon Fraser University; Canada's Michael Smith Genome Sciences Centre; University of British Columbia; Spinal Cord Injury BC","funders":"Imperial Experimental Cancer Medicine Centre; Blood Cancer UK; University of Southampton; F. Hoffmann-La Roche; Kay Kendall Leukaemia Fund; Michael Smith Health Research BC; National Cancer Institute; National Institutes of Health; Cancer Research UK; U.S. Department of Health and Human Services","keywords":"Obinutuzumab; CHOP; Rituximab; Vincristine; Hazard ratio; Internal medicine; Lymphoma; CD20; Medicine; Chemoimmunotherapy; Cyclophosphamide; Oncology; Cancer research; Chemistry; Immunology; Confidence interval; Chemotherapy","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001382596,0.0001329381,0.0003563316,0.00004377184,0.00008383348,0.000006094356,0.0001158595,0.00003289655,0.00005829991],"category_scores_gemma":[0.0008389161,0.00006848414,0.0001256988,0.0002229222,0.0001001046,0.00004921856,0.000055484,0.00005230813,0.000004762633],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00003682504,"about_ca_system_score_gemma":0.0004059833,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00002682884,"about_ca_topic_score_gemma":0.00002387656,"domain_scores_codex":[0.9987738,0.00008508353,0.0003058021,0.000245409,0.0003604106,0.0002295373],"domain_scores_gemma":[0.9975507,0.001604449,0.0001026379,0.0002725069,0.0003684837,0.0001011803],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.08782601,0.0104774,0.122566,0.001949565,0.0005239905,0.0001456637,0.001541602,0.0001321877,0.6913838,0.0001914524,0.001611449,0.08165087],"study_design_scores_gemma":[0.005922462,0.00503477,0.02608485,0.0004361633,0.0001658567,0.00001289867,0.0002648903,0.00002679632,0.8882802,0.00005620359,0.07361258,0.0001023442],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.992337,0.004751613,0.0001191593,0.0009467507,0.0001012266,0.001307231,0.0002582758,0.0000111231,0.0001676612],"genre_scores_gemma":[0.987639,0.0008455642,0.006348832,0.0001465694,0.00008367911,0.0003239889,0.00003291325,0.00001650048,0.004562958],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1968964,"threshold_uncertainty_score":0.2792702,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.032235789902938,"score_gpt":0.3410705343796894,"score_spread":0.3088347444767514,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}